◆ NeutralMEDP
Medpace: 3 Key Takeaways for Long-Term Investors
The Motley Fool·
Medpace reported record net new business awards in Q3 2026, with ending backlog reaching $3.2 billion. The shift in cancellation drivers from funding shortages to clinical failures signals a healthier market. Management deferred 2027 guidance to February but expressed confidence in Q4 performance and normalized competitive pricing.
Read Full Article at The Motley Fool →